For Pediatric Growth Hormone Deficiency (PGHD) and other growth hormone deficiency disorders comprising a $3B+ global market, daily injections of growth hormone (GH) have been the only therapeutic option for over 30 years. Lumos Pharma (Nasdaq:LUMO) hopes to change that paradigm with its differentiated therapeutic candidate, LUM-201, a small tablet that stimulates the body’s natural release of GH.
In November 2020, we advanced our clinical LUM-201 program with the initiation of a Phase 2b trial in PGHD – the OraGrowtH210 Trial – with results expected in mid-2022. If approved, LUM-201 would be the first oral therapeutic to address PGHD. We also believe LUM-201 has potential as a platform therapeutic to work in numerous other indications for which injectable recombinant human growth hormone has been approved, and we are evaluating development opportunities there.
Lumos Pharma’s cash position is solid – with $105.6 million on hand at the end of Q3 and another $26 million coming in January 2021 from a prior sale of our priority review voucher. We believe these funds can support our current operations through OraGrowtH210 Trial read-out and contribute to the expansion of our pipeline through in-licensing or acquisition of another rare disease therapeutic candidate.
Our goal is to develop novel therapies for patients suffering from rare diseases of great unmet need. With the start of our Phase 2b trial in PGHD, we believe we are on our way.
We are headquartered in Austin, TX with additional offices in Ames, IA. For more information and to review our Safe Harbor statement regarding forward-looking comments made herein, please visit our website at www.lumos-pharma.com.